Open-label, long-term study of coadministration of ezetimibe and simvastatin in patients with primary hypercholesterolemia who have not reached LDL [low density lipoprotein]-cholesterol target with HMG [3-hydroxy-3-methyl glutaryl]-CoA [coenzyme A] reductase inhibitors

Trial Profile

Open-label, long-term study of coadministration of ezetimibe and simvastatin in patients with primary hypercholesterolemia who have not reached LDL [low density lipoprotein]-cholesterol target with HMG [3-hydroxy-3-methyl glutaryl]-CoA [coenzyme A] reductase inhibitors

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2017

At a glance

  • Drugs Ezetimibe (Primary) ; Simvastatin
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Sponsors Schering-Plough
  • Most Recent Events

    • 24 Jun 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 24 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top